BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

789 related articles for article (PubMed ID: 12027420)

  • 1. -463 G/A myeloperoxidase promoter polymorphism is associated with clinical manifestations and the course of disease in MPO-ANCA-associated vasculitis.
    Reynolds WF; Stegeman CA; Tervaert JW
    Clin Immunol; 2002 May; 103(2):154-60. PubMed ID: 12027420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathogenesis of PR3-ANCA associated vasculitis.
    Kallenberg CG
    J Autoimmun; 2008; 30(1-2):29-36. PubMed ID: 18162369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histologic and immunohistologic study and clinical presentation of ANCA-associated glomerulonephritis with correlation to ANCA antigen specificity.
    Vizjak A; Rott T; Koselj-Kajtna M; Rozman B; Kaplan-Pavlovcic S; Ferluga D
    Am J Kidney Dis; 2003 Mar; 41(3):539-49. PubMed ID: 12612976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic performance of antineutrophil cytoplasmic antibody tests for idiopathic vasculitides: metaanalysis with a focus on antimyeloperoxidase antibodies.
    Choi HK; Liu S; Merkel PA; Colditz GA; Niles JL
    J Rheumatol; 2001 Jul; 28(7):1584-90. PubMed ID: 11469466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides.
    Kallenberg CG; Heeringa P; Stegeman CA
    Nat Clin Pract Rheumatol; 2006 Dec; 2(12):661-70. PubMed ID: 17133251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No association of G-463A myeloperoxidase gene polymorphism with MPO-ANCA-associated vasculitis.
    Fiebeler A; Borgmann S; Woywodt A; Haller H; Haubitz M
    Nephrol Dial Transplant; 2004 Apr; 19(4):969-71. PubMed ID: 15031357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Value of a new automated fluorescence immunoassay (EliA) for PR3 and MPO-ANCA in monitoring disease activity in ANCA-associated systemic vasculitis.
    Sinico RA; Radice A; Corace C; DI Toma L; Sabadini E
    Ann N Y Acad Sci; 2005 Jun; 1050():185-92. PubMed ID: 16014533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG from myeloperoxidase-antineutrophil cytoplasmic antibody-positive patients stimulates greater activation of primed neutrophils than IgG from proteinase 3-antineutrophil cytosplasmic antibody-positive patients.
    Harper L; Radford D; Plant T; Drayson M; Adu D; Savage CO
    Arthritis Rheum; 2001 Apr; 44(4):921-30. PubMed ID: 11315931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunopathology of ANCA-associated vasculitis.
    Csernok E; Müller A; Gross WL
    Intern Med; 1999 Oct; 38(10):759-65. PubMed ID: 10526937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antineutrophil cytoplasmic antibodies (ANCA): diagnostic utility and potential role in the pathogenesis of vasculitis.
    Malenica B; Rudolf M; Kozmar A
    Acta Dermatovenerol Croat; 2004; 12(4):294-313. PubMed ID: 15588565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antineutrophil cytoplasmic antibody(ANCA)].
    Yoshida M
    Rinsho Byori; 2003 Jul; 51(7):644-8. PubMed ID: 12924248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Review article: Antineutrophil cytoplasmic antibody in small vessel vasculitis].
    Nakano H; Ozaki S
    Rinsho Byori; 2010 May; 58(5):480-9. PubMed ID: 20560457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antineutrophil cytoplasmic antibodies as marker and follow-up parameter of vasculitis and glomerulonephritis].
    Wüthrich RP
    Praxis (Bern 1994); 1994 Oct; 83(43):1202-6. PubMed ID: 7973270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis of myeloperoxidase G-463/A polymorphism in anti-neutrophil cytoplasmic autoantibody-positive vasculitis.
    Rajp A; Adu D; Savage CO
    Clin Exp Immunol; 2007 Aug; 149(2):251-6. PubMed ID: 17521322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antineutrophil cytoplasmic autoantibody testing in vasculitides.
    Gross WL
    Rheum Dis Clin North Am; 1995 Nov; 21(4):987-1011. PubMed ID: 8592745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis of ANCA-associated vasculitis: new possibilities for intervention.
    Kallenberg CG; Stegeman CA; Abdulahad WH; Heeringa P
    Am J Kidney Dis; 2013 Dec; 62(6):1176-87. PubMed ID: 23810690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathogenesis of ANCA-associated vasculitides.
    Kallenberg CG
    Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i59-63. PubMed ID: 21339221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antineutrophil cytoplasmic antibodies (ANCA).
    Radice A; Sinico RA
    Autoimmunity; 2005 Feb; 38(1):93-103. PubMed ID: 15804710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group?
    Millet A; Pederzoli-Ribeil M; Guillevin L; Witko-Sarsat V; Mouthon L
    Ann Rheum Dis; 2013 Aug; 72(8):1273-9. PubMed ID: 23606701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The association of CD18 alleles with anti-myeloperoxidase subtypes of ANCA-associated systemic vasculitides.
    Gencik M; Meller S; Borgmann S; Sitter T; Menezes Saecker AM; Fricke H; Epplen JT
    Clin Immunol; 2000 Jan; 94(1):9-12. PubMed ID: 10607485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.